Skip to main content

BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is an American biotechnology enterprise that develops and commercializes innovative biopharmaceutical products for the treatment of serious rare and ultra-rare genetic diseases. The company researches, develops, and markets enzyme replacement therapies and gene therapies targeting underlying genetic conditions and metabolic disorders. Its principal business activities encompass biopharmaceutical research, clinical development, manufacturing operations, and global commercialization of specialized therapeutics. BioMarin's main revenue drivers are global commercial sales of approved proprietary drugs for rare genetic disorders. As a pioneer in rare disease therapeutics, the company holds a leading market position within its specialized healthcare sector. Headquartered in San Rafael, California, United States, BioMarin Pharmaceutical is publicly listed and traded on NASDAQ.

19 of the funds FundTelligence covers report a position in BioMarin Pharmaceutical.

Legal name
BioMarin Pharmaceutical Inc
Sector
Health Care
Country
United States
Funds holding it
19

Funds holding BioMarin Pharmaceutical

Showing the 8 largest of 19 funds holding it.

Loading...